Home

NICE 'not examining other benefits'of beta interferon

2000-11-16T00:00:00

The National Institute for Clinical Excellence has been accused of failing to consider properly the wider cost-benefits to society of the multiple sclerosis drug, beta interferon.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
  • 10 expert briefings every fortnight (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here